Factors associated with health care utilization in pediatric multiple sclerosis

Marrie, Ruth Ann; O’Mahony, Julia; Maxwell, Colleen J.; Ling, Vicki; Till, Christine; Barlow-Krelina, Emily; Yeh, E. Ann; Arnold, Douglas L.; Bar‐Or, Amit; Banwell, Brenda

doi:10.1016/j.msard.2019.101511

Cited by 7 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants then completed a safety follow-up visit up to 4 weeks after the last dose of study treatment. During the treatment period, clinic visits were conducted on day 1 and weeks 12,16,24,36,48,60,64,72,84,96, and a safety follow-up visit. Follow-up brain MRIs occurred at weeks 16, 24, 64, and 72.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Alroughani

Huppke

Mazurkiewicz‐Bełdzińska³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Background: Pediatric multiple sclerosis (MS) is rare: only 1.5–5% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl fumarate (DMF), an oral MS DMT, in pediatric patients with MS.Methods: CONNECTED is the 96-week extension to FOCUS, a 24-week phase 2 study of patients aged 13–17 years; participants received DMF 240 mg twice daily. Endpoints included (primary) incidence of adverse events (AEs), serious AEs, and DMF discontinuations due to an AE, and (secondary) T2 hyperintense lesion incidence by magnetic resonance imaging and annualized relapse rate (ARR).Results: Twenty participants [median (range) age, 17 (14–18) years; 65% female] who completed FOCUS enrolled into CONNECTED; 17 (85%) completed CONNECTED. Eighteen participants (90%) experienced AEs: the most frequent was flushing (25%). None experienced infections or fever related to low lymphocyte counts. Three participants experienced four serious AEs; none led to DMF discontinuation. Twelve of 17 participants (71%) had no new/newly enlarged T2 lesions from weeks 16–24, two (12%) had one, and one each (6%) had two, three, or five or more lesions [median (range), 0 (0–6)]. Over the full 120-week treatment period, ARR was 0.2, an 84.5% relative reduction (n = 20; 95% confidence interval: 66.8–92.8; p < 0.0001) vs. the year before DMF initiation.Conclusions: The long-term safety and efficacy observed in CONNECTED was consistent with adults, suggesting pediatric and adolescent patients with MS might benefit from DMF treatment.

show abstract

Section: Study Design and Participantsmentioning

confidence: 99%

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Alroughani

Huppke

Mazurkiewicz‐Bełdzińska³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…The disease least affected the social dimension of QoL [32,33,[37][38][39]41,43,44,48] and the physical dimension [32,33,[37][38][39]41,43,44]. The physical dimension of QoL was negatively affected by the disease to a lesser extent than the psycho-social one [34,45].…”

Section: Quality Of Life In Ms Patientsmentioning

confidence: 94%

“…MS patients showed worse QoL in all areas compared to a healthy group/healthy sibling/reference norm [32,33,43,45,47]. Ostojic et al (2016) found lower KIDSCREEN-52 scores only in some dimensions: physical and psychological well-being, autonomy, social support and peers, school environment, and social acceptance [48].…”

Section: Comparison Of the Quality Of Life In Ms Patients With A Healthy Controlmentioning

confidence: 95%

See 1 more Smart Citation

Quality of Life of Children and Adolescents with Multiple Sclerosis—A Literature Review of the Quantitative Evidence

Mrosková

Klímová

Majerníková

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is a chronic disease of the central nervous system that also develops in patients under 18 years of age. The disease negatively affects the quality of life (QoL) of children and adolescents. We conducted a literature review. The aim of the review was to identify the QoL of pediatric patients with MS and assess the factors determining their QoL. Methods: We analyzed studies published between 2000 and 2020 in PubMed, Scopus, Science Direct, Web of Science, and EBSCO databases. Results: In all, 17 studies were included in the review. The most common tool in assessing QoL was the generic module PedsQL. The range of mean/median global score of QoL was 53.8–81.7. The worst QoL was dominantly reported in the school and emotional spheres, on the contrary, the disease’s least determined area of QoL was the social and physical dimension. In particular, disability and fatigue were important predictors of QoL. Conclusions: MS negatively affects the school and emotional spheres in particular, so it is important to pay greater attention to these spheres of life of MS patients. As the review studies pay insufficient attention to the analysis of positive factors and their impact on the QoL of MS patients, research should integrate these phenomena. The use of MS-targeted tools in future research in the pediatric MS population is also appropriate.

show abstract

“…Up to 98% of pediatric patients with MS present with relapsing-remitting MS (RRMS), compared with 84% of adults (1). Pediatric patients tend to have a higher frequency of relapses (10,11) and are more likely to be hospitalized for treatment, highlighting the importance of preventing relapses through effective disease-modifying therapies (DMT) (12).…”

Section: Introductionmentioning

confidence: 99%

Table_1.docx

View full text Add to dashboard Cite

Factors associated with health care utilization in pediatric multiple sclerosis

Cited by 7 publications

References 32 publications

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Quality of Life of Children and Adolescents with Multiple Sclerosis—A Literature Review of the Quantitative Evidence

Table_1.docx

Contact Info

Product

Resources

About